HER2-positive breast cancers respond to anti-HER2 treatments, particularly to monoclonal antibodies such as trastuzumab, which have significantly improved the prognosis for patients with non-metastatic and metastatic disease [4, 5]. Here, ERBB2 is linked to breast cancer.